US physicians require less clinical trial data than their European counterparts before they are comfortable prescribing biosimilars, according to a new report.
The Decision Resources report found that 33% of surveyed U.S. physicians would prescribe a biosimilar based on information from just one Phase III study, as opposed to 20% of physicians in France and Germany.
Go deeper with GlobalData
US physicians are more comfortable with short duration of clinical trials on the whole, the report added.
Decision Resources product director Michael Malecki said that the desire for trials addressing immunogenicity of biosimilars is greater among European physicians.
“This very likely reflects immunogenicity problems with biosimilars erythropoiesis stimulating agents currently on the market in the EU,” said Malecki.
The report found that US and European physicians place the most trust in biotech companies experienced in manufacturing biologics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
